Synopsis: Miller and colleagues analyzed archived annotated breast tumors and evaluated patient data in three public cohorts; they found an inverse association between JAK2 mRNA and risk of recurrence and a correlation between JAK2 expression, improved outcomes, and infiltrating T cells. 
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ABOUT THE COVER
Cytokines are soluble mediators with redundant and pleiotropic activity that aid cellto-cell communication. IL-6 is a prototypical cytokine, and it contributes to acutephase host immune response; its synthesis is induced promptly upon tissue damage or inflammation and ceases when homeostasis is restored. The synthesis of IL-6 is tightly regulated transcriptionally and post-transcriptionally, and its dysregulation has been implicated in the development of autoimmune and chronic inflammatory diseases, including cancer. Stability of the IL-6 mRNA is controlled by the binding of microRNAs and RNA-binding proteins to the AU-rich elements at the 3' untranslated region (UTR). The cover image depicts the regulation of IL-6 synthesis during a pathogenic infection. Bacterial lipopolysaccharide (LPS) binds to the cell-surface Toll-like receptor 4 (TLR4), which activates the synthesis of various proteins, including IL-6, Arid5A, and Regnase-1. Nuclease Regnase-1 binds the 3'UTR of the IL-6 mRNA and accelerates its degradation, while the binding of Arid5a counteracts the destabilizing effect of Regnase-1 on IL-6 mRNA specifically. Therefore, the balance between Arid5a and Regnase-1 plays an important role in IL-6 mRNA stability. When Arid5a dominates the balance of Arid5a and Regnase-1, constitutive overproduction of IL-6 occurs through the stimulation of IL-6R. This positive feedback regulation results in the abnormal production of IL-6 and IL-6-dependent autoimmunity and tumorigenesis. For details, see the Masters of Immunology primer by Tanake and Kishimoto on page 288 of this issue. 
